Verastem Inc (NASDAQ:VSTM)’s stock price dropped 8.8% during mid-day trading on Thursday . The stock traded as low as $1.25 and last traded at $1.25, approximately 2,031,125 shares changed hands during trading. An increase of 1% from the average daily volume of 2,005,943 shares. The stock had previously closed at $1.37.
Separately, ValuEngine upgraded Verastem from a “sell” rating to a “hold” rating in a research report on Monday, November 25th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $5.46.
The stock’s 50-day simple moving average is $1.15 and its two-hundred day simple moving average is $1.30. The company has a debt-to-equity ratio of 6.49, a current ratio of 5.47 and a quick ratio of 5.46. The firm has a market capitalization of $92.94 million, a P/E ratio of -0.91 and a beta of 2.98.
Verastem Company Profile (NASDAQ:VSTM)
Verastem, Inc, a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
Featured Article: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.